ARCHIVES

First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors

This article is from The Cancer Letter archive.

Vol. 34 No. 6 | June 24, 2011

Download PDF Visit The Full Archive

Related Articles

Partial Responses To Zactima In Thyroid Cancer Trial

January 27, 2006

In Brief: FDA Stops Imports Of Counterfeit Adriamychin; Rosenburg: NIH Pay 25-33% That Of Academia

April 22, 1988

Komen Brand Takes Hit After PR Disaster

March 30, 2012

Budge Act Includes Language On Coverage Of Oral Cancer Drugs

August 13, 1993

In Brief: NCI’s Reorganization Plan Picks Up Speed In New Bureaucracy, Could Be Approved Soon

February 29, 1980

Senate Approves Supplemental Funds For NIH and FDA.

May 23, 2008